Related Experiment Videos

Prophylactic platelet transfusion in abciximab-treated patients requiring emergency coronary bypass surgery

The American Journal of Cardiology

|February 19, 1998

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials.

Heart (British Cardiac Society)·2003

The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2001

Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban.

Journal of thrombosis and thrombolysis·2001

Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease.

American heart journal·2001

Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.

American heart journal·2001

Low molecular weight heparin therapy for percutaneous coronary intervention: a practice in evolution.

Journal of thrombosis and thrombolysis·2001

See all related articles